AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Fenebrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Genentech
- 21 May 2019 Planned End Date changed from 1 Mar 2019 to 28 Feb 2021.
- 21 May 2019 Planned primary completion date changed from 1 Mar 2019 to 28 Feb 2021.
- 22 Jan 2018 Planned End Date changed from 29 Dec 2017 to 1 Mar 2019.